A randomized controlled, multicenter trial investigating management of Direct Oral anticoagulant (DOACs) for colorectal polypectomy
- Conditions
- Colorectal polyp
- Registration Number
- JPRN-UMIN000039418
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Not provided
1 Person who has registered in this test. 2 Inflammatory bowel disease, colon polyposis. 3 Patients are receiving systemic steroids, antiplatelet drugs, and multiple anticoagulants continuously. (However, patients who can respond to antiplatelet drugs according to the guidelines of the Japanese Endoscopy Society can be registered.) 4 Blood coagulation dysfunction disease. 5 Women who are pregnant, may become pregnant, or are breastfeeding. 6 Patients with psychosis or psychiatric symptoms seem to have difficulty participating in the study. 7 Active bacterial and fungal infection (has a fever of 38.5 degrees or higher and is associated with bacterial infectivity by diagnostic imaging or bacteriological examination). 8 Uncontrolled hypertension. 9 Respiratory disease requiring continuous oxygen administration. 10 Dialysis. 11 Others who are judged inappropriate by the attending physician (eg, the prescribing physician of the anticoagulant determined that participation in this study was dangerous).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of severe bleeding (uncontrolled intraoperative and postoperative bleeding) associated with polypectomy.
- Secondary Outcome Measures
Name Time Method Rate of postoperative bleeding without emergency endoscopic hemostasis after polypectomy Rate of bleeding requiring blood cessation immediately after polypectomy DOAC dose intensity ( dose intensity) The rate of bleeding in patients who underwent only Cold Snare / Forceps Polypectomy The rate of bleeding by the type of DOAC, the rate of adverse events (the rate of thromboembolism, Incidence).